Ablynx « Terug naar discussie overzicht

Wat na ABLYNX welke aandeln kunnen veel groeien om welke redenen.

3 Posts
[verwijderd]
0
[verwijderd]
0
Merus, bispecifieke antibodies zijn de toekomst. bivoorbeeld: Basel, June 28, 2016 - Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. The agreement is the latest in a series of acquisitions and strategic collaborations between Novartis and biotech companies that have helped bolster its deep and diverse immuno-oncology pipeline.

Traditional monoclonal antibodies target and bind to a single antigen. Bispecific antibodies are engineered to recognize and target two different antigens, which makes them potentially more effective in targeting complex diseases. A T-cell engaging bispecific antibody is able to bind an antigen on a tumor cell with one arm and engage T-cells capable of their destruction with the other.
[verwijderd]
0
Op zoek naar overnamekandidaten in de biotech zoals Ablynx of Tigenix.
Conatus pharmaceuticals lijkt een overnameprooi te gaan worden beurskrant.com/2018/03/06/stijgingspo...
3 Posts
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Markt vandaag

 AEX
913,25  0,00  0,00%  17 mei
 Germany40^ 18.716,50 +0,06%
 BEL 20 4.004,80 0,00%
 Europe50^ 5.069,27 +0,10%
 US30^ 39.995,10 0,00%
 Nasd100^ 18.540,20 0,00%
 US500^ 5.302,48 0,00%
 Japan225^ 38.732,00 0,00%
 Gold spot 2.436,36 +0,88%
 EUR/USD 1,0881 +0,10%
 WTI 79,51 0,00%
#/^ Index indications calculated real time, zie disclaimer

Stijgers

AALBERTS NV 0,00%
ABN AMRO BANK... 0,00%
Accsys 0,00%
ACOMO 0,00%
ADYEN NV 0,00%

Dalers

AALBERTS NV 0,00%
ABN AMRO BANK... 0,00%
Accsys 0,00%
ACOMO 0,00%
ADYEN NV 0,00%